Obesity is associated with a higher degree of synovitis, lower remission, and higher disability, studies showed.
The increased fracture risk may be the result of an increased risk of falls associated with these medications.
Many nontraumatic low intensity complaints in the general population do not reach the threshold for consultation.
The conditions often coexist, and a bidirectional association is suggested.
The incretin-insulin axis and incretin effect are disrupted in patients with RA.
Both romosozumab and calcium help fracture prevention, and most young adults have fractures at nonosteoporotic sites.
Cardiovascular disease prevention and treatment strategies for patients with diabetes may apply.
Residual disease activity is common, and treatment options abound, but for most patients changes are not being made.
In the ARCH trial, romosozumab plus alendronate outperformed alendronate alone in reducing fracture risk.
The latest studies explore new aspects of diagnosis, management, and comorbidities.